BR112012008370B8 - anticorpos monoclonais - Google Patents
anticorpos monoclonaisInfo
- Publication number
- BR112012008370B8 BR112012008370B8 BR112012008370A BR112012008370A BR112012008370B8 BR 112012008370 B8 BR112012008370 B8 BR 112012008370B8 BR 112012008370 A BR112012008370 A BR 112012008370A BR 112012008370 A BR112012008370 A BR 112012008370A BR 112012008370 B8 BR112012008370 B8 BR 112012008370B8
- Authority
- BR
- Brazil
- Prior art keywords
- fibrinogen
- fibrin
- domain
- monoclonal antibodies
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Abstract
anticorpos monoclonais. a presente invenção proporciona um anticorpo isolado que se liga a um domínio yc de fibrina ou fibrinogênio. em vários aspectos, o anticorpo inibe a adesão de micróglia ao domínio yc de fibrina ou fibrinogênio, inibe a ligação mac-1 ao domínio yc de fibrina ou fibrinogênio e/ou suprime sintomas clínicos de encefalomielite autoimune experimental (eae). vários métodos de utilização dos anticorpos, das composições farmacêuticas, dos kits, vetores, células compreendendo os vetores e métodos de geração de anticorpos são fornecidos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24801409P | 2009-10-02 | 2009-10-02 | |
| US61/248,014 | 2009-10-02 | ||
| PCT/US2010/050873 WO2011041518A1 (en) | 2009-10-02 | 2010-09-30 | Monoclonal antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112012008370A2 BR112012008370A2 (pt) | 2016-11-29 |
| BR112012008370B1 BR112012008370B1 (pt) | 2020-12-22 |
| BR112012008370B8 true BR112012008370B8 (pt) | 2021-05-25 |
Family
ID=43826649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012008370A BR112012008370B8 (pt) | 2009-10-02 | 2010-09-30 | anticorpos monoclonais |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US8877195B2 (pt) |
| EP (1) | EP2483416B1 (pt) |
| JP (1) | JP5883389B2 (pt) |
| KR (1) | KR101793221B1 (pt) |
| CN (1) | CN102575277B (pt) |
| AR (1) | AR078490A1 (pt) |
| AU (1) | AU2010300559B2 (pt) |
| BR (1) | BR112012008370B8 (pt) |
| CA (1) | CA2774256C (pt) |
| CL (1) | CL2012000788A1 (pt) |
| CO (1) | CO6440561A2 (pt) |
| CR (1) | CR20120127A (pt) |
| CY (1) | CY1118540T1 (pt) |
| DK (1) | DK2483416T3 (pt) |
| DO (1) | DOP2012000089A (pt) |
| EA (1) | EA023477B1 (pt) |
| ES (1) | ES2614939T3 (pt) |
| GE (2) | GEP20166458B (pt) |
| GT (1) | GT201200096A (pt) |
| HK (1) | HK1168871A1 (pt) |
| HR (1) | HRP20170110T1 (pt) |
| HU (1) | HUE031571T2 (pt) |
| IL (1) | IL218621B (pt) |
| IN (1) | IN2012DN03154A (pt) |
| LT (1) | LT2483416T (pt) |
| MA (1) | MA33704B1 (pt) |
| MX (1) | MX2012003811A (pt) |
| MY (1) | MY159359A (pt) |
| NZ (1) | NZ598770A (pt) |
| PL (1) | PL2483416T3 (pt) |
| PT (1) | PT2483416T (pt) |
| SI (1) | SI2483416T1 (pt) |
| SM (1) | SMT201700083B (pt) |
| TN (1) | TN2012000149A1 (pt) |
| TW (1) | TWI511741B (pt) |
| UA (1) | UA108860C2 (pt) |
| WO (1) | WO2011041518A1 (pt) |
| ZA (1) | ZA201202227B (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8771693B2 (en) | 2009-10-27 | 2014-07-08 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
| US10485780B2 (en) | 2011-03-14 | 2019-11-26 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the treatment of proliferative disorders |
| US10487114B2 (en) | 2011-04-27 | 2019-11-26 | Beth Israel Deaconess Medical Center, Inc. | Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof |
| US9439884B2 (en) | 2011-05-26 | 2016-09-13 | Beth Israel Deaconess Medical Center, Inc. | Methods for the treatment of immune disorders |
| US9730941B2 (en) | 2012-06-07 | 2017-08-15 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the inhibition of Pin1 |
| US9688747B2 (en) | 2013-03-15 | 2017-06-27 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
| US10451611B2 (en) | 2014-01-11 | 2019-10-22 | The J. David Gladstone Institute | Compositions and methods for in vitro assays of fibrin activity |
| WO2016011268A1 (en) | 2014-07-17 | 2016-01-21 | Beth Israel Deaconess Medical Center, Inc. | Atra for modulating pin1 activity and stability |
| US10351914B2 (en) | 2014-07-17 | 2019-07-16 | Beth Israel Deaconess Medical Center, Inc. | Biomarkers for Pin1-associated disorders |
| US10548864B2 (en) | 2015-03-12 | 2020-02-04 | Beth Israel Deaconess Medical Center, Inc. | Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions |
| SG11201910113PA (en) * | 2017-05-02 | 2019-11-28 | Nat Cancer Center Japan | Plasmin-cleavable anti-insoluble fibrin antibody-drug conjugate |
| KR20220161374A (ko) * | 2020-03-31 | 2022-12-06 | 국립연구개발법인 고쿠리츠간켄큐센터 | 피브린에 결합하는 항체 및 당해 항체를 포함하는 의약 조성물 |
| US20240059761A1 (en) * | 2020-12-16 | 2024-02-22 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David | Use of fibrin-targeting immunotherapy to reduce Coronavirus pathogenesis |
| WO2022159776A1 (en) * | 2021-01-21 | 2022-07-28 | Therini Bio, Inc. | Antibodies which bind human fibrin and methods of use |
| CN117794948A (zh) * | 2021-06-18 | 2024-03-29 | 特里尼生物公司 | 结合人纤维蛋白或纤维蛋白原γC结构域的抗体及其使用方法 |
| WO2022266539A2 (en) * | 2021-06-18 | 2022-12-22 | Therini Bio, Inc. | ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN γC DOMAIN AND METHODS OF USE |
| WO2024044583A1 (en) * | 2022-08-22 | 2024-02-29 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Human anti-fibrin antibodies and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030031675A1 (en) * | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
| KR101456770B1 (ko) * | 2004-05-27 | 2014-10-31 | 크루셀 홀란드 비.브이. | 광견병 바이러스를 중화시킬 수 있는 결합 분자 및 그 용도 |
| US7807645B2 (en) * | 2005-09-23 | 2010-10-05 | The Regents Of The University Of California | Method of treating degenerative disorders of the nervous system by administration of fibrinogen fragment |
-
2010
- 2010-09-30 WO PCT/US2010/050873 patent/WO2011041518A1/en active Application Filing
- 2010-09-30 SI SI201031390A patent/SI2483416T1/sl unknown
- 2010-09-30 EA EA201270416A patent/EA023477B1/ru unknown
- 2010-09-30 AU AU2010300559A patent/AU2010300559B2/en active Active
- 2010-09-30 JP JP2012532307A patent/JP5883389B2/ja active Active
- 2010-09-30 NZ NZ598770A patent/NZ598770A/en unknown
- 2010-09-30 CA CA2774256A patent/CA2774256C/en active Active
- 2010-09-30 CN CN201080046037.8A patent/CN102575277B/zh active Active
- 2010-09-30 LT LTEP10821238.2T patent/LT2483416T/lt unknown
- 2010-09-30 DK DK10821238.2T patent/DK2483416T3/en active
- 2010-09-30 GE GEAP201013232A patent/GEP20166458B/en unknown
- 2010-09-30 UA UAA201203044A patent/UA108860C2/ru unknown
- 2010-09-30 ES ES10821238.2T patent/ES2614939T3/es active Active
- 2010-09-30 HU HUE10821238A patent/HUE031571T2/en unknown
- 2010-09-30 GE GEAP201012676A patent/GEP20156214B/en unknown
- 2010-09-30 MX MX2012003811A patent/MX2012003811A/es active IP Right Grant
- 2010-09-30 PL PL10821238T patent/PL2483416T3/pl unknown
- 2010-09-30 PT PT108212382T patent/PT2483416T/pt unknown
- 2010-09-30 KR KR1020127011293A patent/KR101793221B1/ko active IP Right Grant
- 2010-09-30 MY MYPI2012001408A patent/MY159359A/en unknown
- 2010-09-30 EP EP10821238.2A patent/EP2483416B1/en active Active
- 2010-09-30 BR BR112012008370A patent/BR112012008370B8/pt active IP Right Grant
- 2010-10-01 TW TW099133559A patent/TWI511741B/zh active
- 2010-10-01 AR ARP100103578A patent/AR078490A1/es not_active Application Discontinuation
-
2012
- 2012-03-14 IL IL218621A patent/IL218621B/en not_active IP Right Cessation
- 2012-03-16 CR CR20120127A patent/CR20120127A/es unknown
- 2012-03-20 US US13/425,020 patent/US8877195B2/en active Active
- 2012-03-27 ZA ZA2012/02227A patent/ZA201202227B/en unknown
- 2012-03-29 DO DO2012000089A patent/DOP2012000089A/es unknown
- 2012-03-30 GT GT201200096A patent/GT201200096A/es unknown
- 2012-03-30 CL CL2012000788A patent/CL2012000788A1/es unknown
- 2012-03-30 TN TNP2012000149A patent/TN2012000149A1/en unknown
- 2012-04-12 IN IN3154DEN2012 patent/IN2012DN03154A/en unknown
- 2012-04-18 CO CO12064155A patent/CO6440561A2/es active IP Right Grant
- 2012-04-30 MA MA34824A patent/MA33704B1/fr unknown
- 2012-09-27 HK HK12109512.6A patent/HK1168871A1/zh unknown
-
2017
- 2017-01-23 HR HRP20170110TT patent/HRP20170110T1/hr unknown
- 2017-01-30 CY CY20171100132T patent/CY1118540T1/el unknown
- 2017-02-08 SM SM201700083T patent/SMT201700083B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012008370B8 (pt) | anticorpos monoclonais | |
| CY1121536T1 (el) | Ανθρωπινα αντισωματα εναντι-αλφα-συνουκλεϊνης | |
| CY1123518T1 (el) | Ανθρωπινα αντισωματα enanti-tau | |
| BR112019005292A2 (pt) | anticorpos para siglec-15 e métodos de uso dos mesmos. | |
| Bertolaccini et al. | Prevalence of antibodies to prothrombin in solid phase (aPT) and to phosphatidylserine-prothrombin complex (aPS/PT) in patients with and without lupus anticoagulant | |
| BR112013010213A2 (pt) | anticorpos que unem ligantes solúveis de receptores de célula t | |
| BR112013027021A2 (pt) | anticorpos anti-igf-1r e anti-erbb3 monoespecíficos e biespecíficos | |
| BR112016003665A2 (pt) | anticorpos e ensaios para detecção do receptor 1 de folato | |
| MA35620B1 (fr) | Compositions pour le traitement de l'arthrite rhumatoïde et procédés d'utilisation desdites compositions | |
| BR112015014833A2 (pt) | anticorpo isolado ou fragmento de ligação de antígeno deste, ácido nucléico isolado, célula hospedeira, método de ensaiar uma amostra de tecido removido de um humano para expressão de pd-l1, estojo, e, composição de anticorpo que compreende uma mistura de moléculas do anticorpo | |
| EA200971131A1 (ru) | Биомаркеры для прогнозирования чувствительности или отсутствия чувствительности к анти-фно агентам | |
| Schierwagen et al. | Serum markers of the extracellular matrix remodeling reflect antifibrotic therapy in bile-duct ligated rats | |
| BRPI0814343A2 (pt) | Materiais e métodos para a seleção da sexagem do esperma | |
| Palmer et al. | Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease | |
| BR112021012667A2 (pt) | Proteínas de ligação anti-pd-1 e métodos de uso destas | |
| ATE437182T1 (de) | Diagnose von allergischen erkrankungen, atopischen erkrankungen und/oder autoimmunerkrankungen durch nachweis von autoantikörpern gegen cd28 in humanem serum | |
| NZ601643A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| MX2013010571A (es) | Ensayo de diagnostico de anticuerpo. | |
| BR112013025287A2 (pt) | ensaios com receptores de esteroide para detectar células tumorais | |
| WO2007084570A3 (en) | High sensitivity secretagogin assays and their uses for diagnosis and/or prognosis | |
| WO2019002518A3 (en) | ACTIVE BINDING MOLECULE FXII | |
| Murray et al. | Demonstration of the specificity of human autoantibody responses to tumor-associated antigens | |
| TH132228B (th) | โมโนโคลนอล แอนติบอดี (Monoclonal anitbody) | |
| BR112013006631A2 (pt) | métodos e composições para a avaliação de lesão renal utilizando ácido hialurônico | |
| EA201001340A1 (ru) | Улучшенный аналитический способ для определения латентного гепатита с, его применения и соответствующий диагностический набор |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/12/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/09/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |